leo 271 f has been researched along with Prostatic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forshell, GP; Fritjofsson, A; Gunnarsson, PO; Norlén, BJ | 1 |
| Budman, DR; Kreis, W; Liu, XM; Wang, LG | 1 |
| Andersson, SB; Björk, P; Fritjofsson, A; Gunnarsson, PO; Norlén, BJ | 1 |
3 other study(ies) available for leo 271 f and Prostatic Neoplasms
| Article | Year |
|---|---|
Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt).
Topics: Administration, Oral; Aged; Carcinoma; Estradiol; Estramustine; Estrone; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Prostatic Neoplasms; Time Factors | 1981 |
Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Topics: Androgen Antagonists; Antineoplastic Agents, Alkylating; Binding, Competitive; Estramustine; Estrogens; Estrone; Genes, Reporter; HeLa Cells; Humans; Kinetics; Luciferases; Male; Metribolone; Mutagenesis; Nitrogen Mustard Compounds; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Transcriptional Activation; Transfection; Triamcinolone Acetonide; Tumor Cells, Cultured | 1998 |
Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer.
Topics: Aged; Carcinoma; Carrier Proteins; Estradiol; Estramustine; Estrone; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Prostate; Prostatic Neoplasms; Prostatic Secretory Proteins | 1988 |